Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging

Pediatric Infectious Disease Journal

Volumn 16, Issue 6, 1997, Pages 572-578

  Richard, David A ^a   Nousia Arvanitakis, Sanda ^b   Sollich, Veronika ^c   Hampel, Barbara J ^d   Sommerauer, Bernd ^d   Schaad, Urs B ^e   Sardet, A ^f   Bromme S ^f   Kloditz E ^f   Lietz, T ^f   Schille, R ^f   Posselt, H G ^f   Noll, S ^f   Sollich, V ^f   Zimmermann, T ^f   Barmeier Wasmuth H ^f   Wahn, U ^f   Weber, A ^f   Magdorf, K ^f   Wacker, F ^f   Troger J ^f   Lyle, M ^f   Schmidt, A ^f   Preuss, I ^f   Krasemann, C ^f   Nikolaidis, P ^f   Peonides, A ^f   Skalidopoulos, S ^f   Sotiriadis, G ^f   Gyurkovits, K ^f   Bolbas, K ^f   Rivlin, J ^f   Mastella, G ^f   Cipolli, M ^f   Trogu, P ^f   Barreto, C ^f   Lara, E ^f   Egner, J ^f   Hauptmann, M ^f   Wedgwood, J ^f   more..

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d BAYER AG   (Germany)

^e UNIVERSITY OF BASEL   (Switzerland)

^f NONE

Author keywords

Antipseudomonas; Ciprofloxacin; Cystic fibrosis; Pediatrics; Skeletal toxicity

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; TOBRAMYCIN;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; GRAM NEGATIVE INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; CARTILAGE; CEFTAZIDIME; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 0030972776     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199706000-00007     Document Type: Article

References (30)

1. Boxerbaum B. The art and science of the use of antibiotics in cystic fibrosis. Pediatr Infect Dis J 1982;1:381-3.
2. Hoiby N, Friis B, Jense K, et al. Antimicrobial chemotherapy in cystic fibrosis patients. Acta Paediatr Scand 1982;71(Suppl 310):75-100.
3. Smith AL. Antibiotic therapy in cystic fibrosis: evaluation of clinical trials. J Pediatr 1986;108:866-70.
4. Schaad UB, Desgrandchamps D, Kraemer R. Antimicrobial therapy of Pseudomonas pulmonary exacerbations in cystic fibrosis: a prospective evaluation of netilimicin plus azlocillin versus netilmicin plus ticarcillin. Acta Paediatr Scand 1986; 75:128-38.
5. Schaad UB, Wedgwood-Krucko J, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987;111:599-605.
6. Schaad UB, Wedgwood-Krucko J, Guenin U, Buehlmann R, Kraemer R. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis 1989;810:858-65.
7. Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. Am J Med 1987; 82(Suppl 4A):180-4.
8. Scully BE, Parry MF, Neu HC, Mandell W. Oral ciprofloxacin therapy on infections due to Pseudomonas aeruginosa. Lancet 1986;1:819-22.
9. Schaad UB, Salam MA, Aujard Y, et al. Use of floroquinolones in pediatrics: consensus report of the International Society of Chemotherapy commission. Pediatr Infect Dis J 1995; 14:1-9.
10. Rubio TT. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diag Microbiol Infect Dis 1990;13:153-5.
11. Simon C. Im Tierexperiment beobachtete Knorpelschädigung durch Chinolone. Adv Antimicrob Antineoplast Chemother 1984;3:785-8.
12. Schlüter G. Toxicology of ciprofloxacin. In: Neu HC, Weuta H, eds. Proceedings of the First International Ciprofloxacin Workshop. Amsterdam: Excerpta Medica, 1986:61-70.
13. Schaad UB, Wedgwood-Krucko J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 1987;15:165-8.
14. Dab I, Desmyttere S, Malfroot, A. Repeated use of ciprofloxacin in a pediatric cystic fibrosis population. Adv Antimicrob Antineoplast Chemother 1992;11:143-6.
15. Enenkel S, Bender S, Posselt HG. Treatment with quinolones of pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis [Abstract 359]. In: Third International Symposium on New Quinolones, Vancouver, 1990:444.
16. Kuhn RJ, Kanga JF, Palmejar AR, Rubio T. Retrospective review of ciprofloxacin for acute pulmonary exacerbations in pediatric CF patients [Abstract 212]. Pediatr Pulmonol 1990; (Suppl 5):246.
17. Shwachman H. In: Kendig EL, ed. Disorders of the respiratory tract in children. Philadelphia: Saunders, 1967:541.
18. Chrispin AR, Norman AP. The systematic evaluation of the chest radiograph in cystic fibrosis. Pediatr Radiol 1974;2: 101-6.
19. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. Document M7-A. Villanova, PA: National Committee for Clinical Laboratory Standards, 1985.
20. König H, Sauter R, Deimling M, Vogt M. Cartilage disorders: comparison of spin-echo, CHESS, and FLASH sequence MR images. Radiology 1987;164:753-8.
21. Marks MI. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. J Pediatr 1981;98: 173-9.
22. Hoiby N. Microbiology of lung infections in CF patients. Acta Paediatr Scand 1982;71(Suppl 301):33-54.
23. Ingham B, Brentnall DW, Dale EA, McFadzean JA. Arthropathy induced by antibacterial fused n-alkyl-4-pyridone-3-carboxylic acids. Toxicol Lett 1977;1:21-6.
24. Gough A, Barsoum NJ, Mitchell L, McGuire EJ, de la Iglesia FA. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol 1979;51:177-87.
25. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988;10(Suppl 1):S141-6.
26. Stahlman R, Merker HJ, Hinz N, Chahoud I, Heger W, Neubert D. Ofloxacin in juvenile non-human primates and rats: arthropathia and drug plasma concentrations. Arch Toxicol 1990;64:193-204.
27. Phillips BM, David TJ. Pathogenesis and management of arthropathy in cystic fibrosis. J R Soc Med 986;79(Suppl 12):44-50.
28. Schaad UB, Wedgwood J, Ruedeberg A, Kraemer R, Hampel B. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatr Infect Dis J 1997;16:106-11.
29. Church DA, Kanga JF, Kuhn RJ, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatr Infect Dis J 1997;16:97-105.
30. Pradhan KM, Arora NK, Jena A, Susheela Ak, Bhan MK. Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Acta Paediatr 1995;84:555-60.